Celyad Oncology S.A.

Celyad Oncology SA is a clinical-stage biopharmaceutical company specializing in the development of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. The company's lead product candidates include allogeneic and autologous CAR-T candidates for the treatment of metastatic colorectal cancer, relapsed/refractory multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes. Additionally, Celyad Oncology SA has a preclinical candidate for the treatment of solid tumors. The company generates revenue through the development and potential commercialization of its CAR-T therapies, as well as through licensing agreements and research collaborations with other biopharmaceutical companies.

Products

• CYAD-101 (allogeneic CAR-T candidate)

• CYAD-211 (shRNA-based allogeneic CAR-T candidate)

• CYAD-02 (autologous CAR-T candidate)

• CYAD-203 (non-gene edited allogeneic CAR-T candidate)